Recent advancements in kidney stone management include novel access sheaths and miniaturized scopes, enhancing treatment options for patients. AI integration in kidney stone management offers ...

“I feel a lot of providers, with Antiva being available, have unfortunately reserved use of this great FDA-approved agent for BCG-unresponsive patients because of the supply issue with BCG," says ...

“It definitely makes it easier for providers [to counsel patients]," says Landon Trost, MD. With the FDA’s recent class-wide labeling changes for testosterone products 1, urologist Landon Trost, MD, ...

Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices? What challenges do you anticipate in operationalizing TAR-200 and other novel delivery ...

The study utilized 68Ga-PSMA-11 PET imaging to assess outcomes in prostate cancer patients treated with 177Lu-PSMA-617, focusing on whole-body SUVmean as a key parameter. Higher whole-body SUVmean ...

“The benefit of being here at the University of Minnesota is that we have a bunch of different types of settings to be able to trial this," says Hailey Frye. A study from the American Urological ...

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall ...

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, ...

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology. The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an ...

“The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant setting," says Joshua J. Meeks, MD, PhD. “The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant ...

A panelist discusses how Matching-Adjusted Indirect Comparison (MAIC) analyses are limited by potential unmeasured confounding factors, small effective sample sizes after matching, and reliance on ...

A panelist discusses how MAIC (Matching-Adjusted Indirect Comparison) methodology addresses the lack of head-to-head clinical trials in metastatic hormone-sensitive prostate cancer (mHSPC) by ...